News
TRUFF
0.021
+0.48%
0.000
Rhelion Subsidiary Filament to Supply Psilocybin for UCSF Trial on Meth Use Disorder in People With HIV
TipRanks · 9h ago
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Licence Agreement with the University of California, San Francisco for a Phase 2 Trial of Psilocybin in Methamphetamine Use Disorder Among People with HIV
Newsfile · 10h ago
Weekly Report: what happened at TRUFF last week (0928-1002)?
Weekly Report · 3d ago
Psychedelic: Psyence BioMed announces exclusive U.S. ibogaine license
TipRanks · 10/01 14:30
Rhelion Unit Ships Psilocybin Candidate for PTSD Trial in Calgary
TipRanks · 09/29 12:08
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Calgary for Phase 2 Trial of Psilocybin-Assisted Therapy for PTSD in Survivors of Intimate Partner Violence
Newsfile · 09/29 11:53
Weekly Report: what happened at TRUFF last week (0921-0925)?
Weekly Report · 09/28 09:25
Rhelion’s Filament Unit Boosts Psilocybin Supply for Landmark Italian Depression Trial
TipRanks · 09/25 14:07
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resistant Depression in Italy
Newsfile · 09/25 12:48
Psychedelic: Optimi completes psilocybin production for Phase 2 trial
TipRanks · 09/24 14:30
Rhelion Subsidiary Filament Health Wins New Canadian Patent for Natural Psilocybin
TipRanks · 09/22 13:12
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New Canadian Patent, Extending the Broadest Natural Psilocybin Patent Estate
Newsfile · 09/22 11:33
Rhelion Subsidiary Supplies Psilocybin for Phase 3 Palliative Care Trial
TipRanks · 09/21 12:08
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Delivers PEX010 to Bruyere Health Research Institute's Phase 3 Trial of Microdose Psilocybin in Palliative Care
Newsfile · 09/21 11:49
Weekly Report: what happened at TRUFF last week (0914-0918)?
Weekly Report · 09/21 09:25
Psychedelic: Definium’s LSD-based drug meets endpoints in GAD study
TipRanks · 09/17 13:55
Rhelion’s Filament Health inks psilocybin supply deal with Dutch research centre
TipRanks · 09/17 13:43
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose Psilocybin
Newsfile · 09/17 11:52
Rhelion’s Filament Health to Supply Psilocybin Candidate PEX010 for USC Mindfulness Trial
TipRanks · 09/16 10:33
Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the University of Southern California for PEX010 in a Trial for Psilocybin-Assisted Mindfulness Therapy
Newsfile · 09/15 11:59
More
Webull provides a variety of real-time TRUFF stock news. You can receive the latest news about Rhelion Life Sciences Corp through multiple platforms. This information may help you make smarter investment decisions.
About TRUFF
Rhelion Life Sciences Corp., formerly Red Light Holland Corp., is a science and research led company advancing the natural psychedelic drug discovery and development sector. Through its wholly owned subsidiary Filament Health Corp., the Company is developing naturally derived psilocybin drug candidates, including its patented PEX010, and supporting clinical research and compassionate use programs with institutions around the world. PEX010 is its standardized natural psilocybin drug candidate, studied across 80+ clinical trials worldwide, including FDA-authorized programs in depression, PTSD, cancer-related distress, and substance use disorders. Its products also include IBEXX and MB2500. IBEXX is its botanical ibogaine drug candidate. MB2500 is its whole-leaf coca extract drug candidate. It also operates in the Netherlands' legal adult-use market and supports voluntary data collection and research to help advance the scientific understanding of natural psychedelics.